SCHEMBL10190239

SCHEMBL10190239

Cc1cc(OC2CN(C(=O)OC(C)(C)C)C2)ccc1CN1CCC(C)(CO)CC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 7/20 0.43
PLA2G1B P04054 1/20 0.39
POLB P06746 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
USP30 Q70CQ3 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
GPR119 Q8TDV5 3/20 0.37
RORC P51449 1/20 0.37
KMT2A Q03164 2/20 0.37
JAK2 O60674 1/20 0.37
GNRHR P30968 1/20 0.37
S1PR1 P21453 1/20 0.37
S1PR5 Q9H228 1/20 0.37
MEN1 O00255 1/20 0.36
KCNH2 Q12809 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL326617 0.88 MCHR1 (0.47) MCHR1PLA2G1BPOLBATG4BKMT2A
SCHEMBL327553 0.79 PLA2G1B (0.40) MCHR1PLA2G1BPOLBATG4BKMT2A
SCHEMBL10190070 0.77 KCNH2 (0.56) MCHR1USP30GPR119KMT2AJAK2
SCHEMBL10190100 0.77 ADRB2 (0.53) MCHR1USP30HRH3GPR119KMT2A
SCHEMBL326652 0.77 MCHR1 (0.73) MCHR1KCNH2
SCHEMBL326650 0.77 MCHR1 (0.68) MCHR1HRH3KCNH2
SCHEMBL214858 0.75 USP30 (0.45) USP30HRH3GPR119
SCHEMBL10190094 0.75 MCHR1 (0.59) MCHR1USP30HRH3GPR119KCNH2
SCHEMBL10190036 0.74 MCHR1 (0.63) MCHR1POLBHRH3KMT2AMEN1
SCHEMBL321227 0.71 KCNH2 (0.54) MCHR1USP30HRH3GPR119KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590969-B1 Therapeutic agents 976 ASTRAZENECA AB (SE) 2014-10-15 EP disclosed
US-8546375-B2 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds ASTRAZENECA AB (SE) 2013-10-01 US disclosed
US-8546375-B2 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds ASTRAZENECA AB (SE) 2013-10-01 US disclosed
WO-2012004588-A2 THERAPEUTIC AGENTS 976 ASTRAZENECA AB (SE) 2012-01-12 WO disclosed
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS ASTRAZENECA AB (SE) 2012-01-12 US disclosed
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS ASTRAZENECA AB (SE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS TYR, MC2R, MC1R MCHR1 9/4885PLA2G1B 3791/4885POLB 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.